Compliance Rate
Compliance Rate
100.0%
Compliant submissions
1
Incompliant submissions
0
Total trials
1
My Organizations' Clinical Trials
Showing 1450 of 2228 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/30/02
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 10/31/98
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 01/16/24
End: 12/03/25
Due: 12/03/26
Phase: N/A
Priority: Normal
Start: 10/31/12
End: 01/31/13
Due: 01/31/14
Phase: N/A
Priority: Normal
Start: 08/31/05
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 04/27/22
End: 06/12/24
Due: 06/12/25
Phase: N/A
Priority: Normal
Start: 01/31/11
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 11/30/99
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 05/31/09
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 06/30/13
End: 07/31/13
Due: 07/31/14
Phase: N/A
Priority: Normal
Start: 04/30/13
End: 06/30/13
Due: 06/30/14
Phase: N/A
Priority: Normal
Start: 02/28/98
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 01/26/15
End: 10/18/16
Due: 10/18/17
Phase: N/A
Priority: Normal
Start: 06/30/09
End: 01/31/13
Due: 01/31/14
Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients
Phase: N/A
Priority: Normal
Start: 05/31/00
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 02/29/04
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 06/30/07
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 04/27/21
End: 12/21/23
Due: 12/21/24
Phase: N/A
Priority: Normal
Start: 04/18/23
End: 07/14/23
Due: 07/14/24
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
Phase: N/A
Priority: Normal
Start: 03/17/16
End: 08/26/16
Due: 08/26/17
Phase: N/A
Priority: Normal
Start: 03/01/10
End: 02/18/11
Due: 02/18/12
Phase: N/A
Priority: Normal
Start: 09/01/15
End: 05/25/16
Due: 05/25/17
Phase: N/A
Priority: Normal
Start: 07/31/14
End: 01/31/15
Due: 01/31/16
Phase: N/A
Priority: Normal
Start: 09/30/03
End: 08/31/04
Due: 08/31/05
Phase: N/A
Priority: Normal
Start: 11/04/19
End: 03/26/21
Due: 03/26/22